Q2 2025

Filed Aug 6, 2025 · 10-Q · 37 days after period end · 0001438533-25-000046

Q2 2025 · 10-Q

Revenue

$114.45M

+111.5% vs Q2 2024

Net Income

-$12.76M

N/M vs Q2 2024

EPS Diluted

-$0.14

N/M vs Q2 2024

Operating Income-$12,650,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2025	Q2 2024	Q2 2023	Q2 2022
Revenue	$114.45M	$54.12M	$32.20M	$28.63M
Net Income	-$12.76M	-$70.41M	-$85.63M	-$67.03M
EPS Diluted	-$0.14	-$0.91	-$1.13	-$1.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR